- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ImageneBio: Vorstand genehmigt Anreizplan 2025 zur Mitarbeitergewinnung | 2 | Investing.com Deutsch | ||
| Fr | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 63 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| Di | ImageneBio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07. | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 205 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 24.07. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 23.07. | Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company | 1 | Investing.com | ||
| 23.07. | Ikena Oncology, Inmagene Biopharmaceuticals appoint Kristin Yarema, as CEO | 1 | Seeking Alpha | ||
| 23.07. | Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm | 5 | Investing.com | ||
| 23.07. | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 163 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen | |
| 22.07. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Ikena Oncology ändert Vergütungsvereinbarung für Dr. Jotin Marango vor Fusion | 1 | Investing.com Deutsch | ||
| 15.07. | Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals | 151 | GlobeNewswire (Europe) | Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc.... ► Artikel lesen | |
| 12.07. | ISS And Glass Lewis Support Ikena Oncology's Share Issuance For Proposed Inmagene Merger | 5 | RTTNews | ||
| 11.07. | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.07. | Ikena Oncology, Inc.: Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals | 88 | GlobeNewswire (Europe) | BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," the "Company") today announced that Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass... ► Artikel lesen | |
| 01.07. | Ikena Oncology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.06. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 08.05. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,950 | -1,36 % | Evotec Aktie kämpft sich zurück: Wie stabil ist der Anstieg? | Die Evotec Aktie hat einen großen Teil des Kurssturzes vom vergangenen Montag wettgemacht und zeigt sich zum Wochenstart stabilisiert. Am Freitag legte die Biotech-Aktie kräftig zu und schloss bei 7... ► Artikel lesen | |
| BIOGEN | 110,80 | -2,85 % | Biogen Q2 Results Top Estimates; Boosts FY25 Outlook | WESTON (dpa-AFX) - Biotechnology company Biogen, Inc. (BIIB) reported Thursday that net income attributable to the company for the second quarter grew to $634.8 million or $4.33 per share from... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,280 | -3,45 % | Aktionäre von Palatin Technologies stimmen Reverse-Aktiensplit und Vorstandswahlen zu | ||
| MAINZ BIOMED | 1,330 | -23,34 % | MAINZ BIOMED N.V. - F-1, Registration statement for certain foreign private issuers | ||
| VIKING THERAPEUTICS | 28,200 | -0,18 % | Is Viking Therapeutics the Next Big Biotech Bet? | ||
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| ABIVAX | 61,60 | +0,33 % | Abivax: Biotech-Highflyer schließt Kapitalerhöhung ab | Abivax hat die Platzierung von 11.679.400 American Depositary Shares in den USA abgeschlossen. Durch das öffentliche Angebot, einschließlich der vollständig ausgeübten Mehrzuteilungsoption der Konsortialbanken... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,790 | -1,03 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| GALAPAGOS NV | 28,220 | -0,14 % | Galapagos NV: Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors | New Directors bring deep commercial, operational, and transaction experience to the Board
Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,310 | +0,65 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| CENTOGENE | 0,120 | -7,69 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,770 | -9,98 % | Coherus Oncology, Inc.: Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | ||
| SENSEI BIOTHERAPEUTICS | 10,400 | +40,35 % | Sensei Biotherapeutics präsentiert Daten zu Krebstherapie auf dem ESMO-Kongress 2025 | ||
| CYTOMX THERAPEUTICS | 2,028 | 0,00 % | Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings) | ||
| CYTOKINETICS | 32,400 | +1,89 % | Raymond James downgrades Cytokinetics stock rating to Market Perform |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,620 (-3,46 %) liegt der Kurs bei 17,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.